Trial intelligence / Profile preview

Ensovibep in symptomatic COVID-19

NCT04834856Phase 2Completed

Sponsor
Molecular Partners AG
Start
Apr 2021
Primary completion
Aug 2021
Modality
Carrier/Scaffold Proteins
Countries
1
01

Overview

A Phase 2 trial of ensovibep in coronavirus disease 2019 (COVID-19), sponsored by Molecular Partners AG. Started Apr 2021; status: completed.

02

Drugs

ensovibep
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on NCT04834856.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04834856.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call